Regenexx Bio said Suravec wet AMD pivotal data are expected this quarter, RGX202’s full BLA filing is planned for the first quarter of 2027, and cash, cash equivalents and marketable securities totaled $251 million at September 30, 2026.
RGNX · REGENXBIO Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within 12 months from the issuance date of our consolidated financial statements for the three and nine months ended September 30, 2026 included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
REGENXBIO reported positive pivotal RGX-202 results and plans a BLA submission in the first quarter of 2027, while RGX-121 remains on clinical hold. The wet AMD pivotal program completed enrollment, with topline data expected in the fourth quarter of 2026.
REGENXBIO remains on track to submit the RGX-202 BLA in Q1 2027, while reporting $251.0 million in cash, cash equivalents and marketable securities and a $40.7 million net loss for the third quarter ended September 30, 2026.
Kenneth T. Mills resigned from the board effective October 21, 2026, to focus on his new role as chief executive officer of another company. The board appointed George Migausky as Chairman, and Daniel Tassé stepped down as Lead Independent Director but remains a board member.
On September 23, 2026, REGENXBIO Inc. entered a settlement with Sarepta that requires a $39.0 million payment to REGENXBIO within 10 days of the effective date and terminates all ongoing patent litigation over ELEVIDYS-related patents.